- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04973605
En fase 1b/2-studie av BGB-11417 i monoterapi og i ulike kombinasjoner med deksametason og karfilzomib ved multippelt myelom
En fase 1b/2-dose-eskalerings- og kohort-utvidelsesstudie for å bestemme sikkerheten og effekten av BGB-11417 som monoterapi, i kombinasjon med deksametason og karfilzomib/deksametason hos pasienter med residiverende/refraktært myelomatose og t)(11;
The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM) and chromosomal translocation t(11;14).
The study investigates sonrotoclax alone and in combination with dexamethasone and other agents, including carfilzomib, daratumumab, and pomalidomide.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.
Studietype
Registrering (Antatt)
Fase
- Fase 2
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: BeOne Medicines
- Telefonnummer: 1.877.828.5568
- E-post: clinicaltrials@beonemed.com
Studiesteder
-
-
Australian Capital Territory
-
Garran, Australian Capital Territory, Australia, ACT 2605
- Rekruttering
- Canberra Hospital
-
-
New South Wales
-
Kingswood, New South Wales, Australia, NSW 2747
- Rekruttering
- Nepean Hospital
-
-
Victoria
-
Clayton, Victoria, Australia, VIC 3168
- Rekruttering
- Monash Health
-
Fitzroy, Victoria, Australia, VIC 3065
- Rekruttering
- St Vincents Hospital Melbourne
-
Melbourne, Victoria, Australia, VIC 3004
- Rekruttering
- The Alfred Hospital
-
-
Western Australia
-
Perth, Western Australia, Australia, WA 6000
- Rekruttering
- Royal Perth Hospital
-
-
-
-
-
Brasília, Brasil, 70200-730
- Rekruttering
- Hospital Sirio Libanes Brasilia
-
Brasília, Brasil, 70390140
- Rekruttering
- Instituto Dor de Pesquisa E Ensino Distrito Federal
-
Porto Alegre, Brasil, 90110-270
- Rekruttering
- Centro Gaucho Integrado de Oncologia Hospital Mae de Deus
-
Salvador, Brasil, 41253-190
- Rekruttering
- Hospital Sao Rafael (Rede Dor)
-
São Paulo, Brasil, 05652-900
- Rekruttering
- Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
-
São Paulo, Brasil, 01401-004
- Rekruttering
- Instituto Dor de Pesquisa E Ensino Sao Paulo
-
São Paulo, Brasil, 01308-050
- Rekruttering
- Hospital Sirio Libanes
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1Z2
- Rekruttering
- Cross Cancer Institute
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 4E6
- Rekruttering
- British Columbia Cancer Agency the Vancouver Centre
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- Rekruttering
- Princess Margaret Cancer Centre
-
-
-
-
Alabama
-
Birmingham, Alabama, Forente stater, 35294-0004
- Rekruttering
- University of Alabama At Birmingham Hospital
-
-
California
-
Duarte, California, Forente stater, 91010-3012
- Rekruttering
- City of Hope National Medical Center
-
Irvine, California, Forente stater, 92618-2377
- Rekruttering
- City of Hope Irvine Lennar
-
-
Florida
-
Miami, Florida, Forente stater, 33136-2107
- Rekruttering
- University of Miami
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30322-1013
- Rekruttering
- Emory University Winship Cancer Center
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60637-1443
- Rekruttering
- University of Chicago Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02114
- Fullført
- Massachusetts General Hospital
-
-
Missouri
-
St Louis, Missouri, Forente stater, 63110-1010
- Rekruttering
- Washington University School of Medicine
-
-
New Jersey
-
Hackensack, New Jersey, Forente stater, 07601-1915
- Rekruttering
- Hackensack University Medical Center
-
-
New York
-
New York, New York, Forente stater, 10065-6800
- Rekruttering
- Memorial Sloan Kettering Cancer Center Mskcc
-
-
Ohio
-
Columbus, Ohio, Forente stater, 43210-1240
- Rekruttering
- The James Cancer Hospital and Solove Research Institute At Ohio State University
-
-
Utah
-
Salt Lake City, Utah, Forente stater, 84112-5550
- Rekruttering
- Huntsman Cancer Institute
-
-
Washington
-
Seattle, Washington, Forente stater, 98195
- Rekruttering
- University of Washington
-
-
Wisconsin
-
Madison, Wisconsin, Forente stater, 53792-0001
- Rekruttering
- University of Wisconsin Carbone Cancer Center
-
Milwaukee, Wisconsin, Forente stater, 53226-3522
- Rekruttering
- Medical College of Wisconsin
-
-
-
-
-
Poitiers, Frankrike, 86000
- Fullført
- Chu de Poitiers Site de La Mileterie
-
-
-
-
-
Alexandroupoli, Hellas, 68100
- Rekruttering
- University Hospital of Alexandroupolis
-
Athens, Hellas, 115 28
- Rekruttering
- General Hospital of Athens Alexandra
-
-
-
-
-
Ancona, Italia, 60020
- Rekruttering
- Azienda Ospedaliera Universitaria Delle Marche
-
Bari, Italia, 70124
- Rekruttering
- Azienda Ospedaliera Policlinico Di Bari
-
Bologna, Italia, 40138
- Rekruttering
- Policlinico Sorsola Malpighi, Aou Di Bologna
-
Meldola, Italia, 47014
- Rekruttering
- Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori Irst
-
Milan, Italia, 20141
- Rekruttering
- Istituto Europeo Di Oncologia
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 100044
- Rekruttering
- Peking University Peoples Hospital
-
Beijing, Beijing Municipality, Kina, 100000
- Rekruttering
- Peking University Third Hospital
-
Beijing, Beijing Municipality, Kina, 100020
- Rekruttering
- Beijing Chao Yang Hospital
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, Kina, 400030
- Rekruttering
- Chongqing Cancer Hospital
-
-
Fujian
-
Fuzhou, Fujian, Kina, 350001
- Fullført
- Fujian Medical University Union Hospital
-
Xiamen, Fujian, Kina, 361003
- Fullført
- The First Affiliated Hospital of Xiamen University
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510060
- Rekruttering
- Sun Yat Sen University Cancer Center
-
-
Hebei
-
Shijiazhuang, Hebei, Kina, 050000
- Fullført
- The Second Hospital of Hebei Medical University
-
-
Henan
-
Zhengzhou, Henan, Kina, 450000
- Rekruttering
- Henan Cancer Hospital
-
Zhengzhou, Henan, Kina, 450052
- Aktiv, ikke rekrutterende
- The First Affiliated Hospital of Zhengzhou University
-
-
Hubei
-
Wuhan, Hubei, Kina, 430022
- Rekruttering
- Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
-
-
Hunan
-
Changsha, Hunan, Kina, 410013
- Fullført
- Hunan Cancer Hospital
-
-
Jiangsu
-
Nanjing, Jiangsu, Kina, 210029
- Rekruttering
- Jiangsu Province Hospital
-
-
Jiangxi
-
Nanchang, Jiangxi, Kina, 332000
- Rekruttering
- The First Affiliated Hospital of Nanchang University Branch Xianghu
-
-
Liaoning
-
Shenyang, Liaoning, Kina, 110001
- Rekruttering
- The First Hospital of China Medical University
-
-
Shandong
-
Qingdao, Shandong, Kina, 266000
- Rekruttering
- Qingdao Municipal Hospital
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina, 200032
- Rekruttering
- Affiliated Zhongshan Hospital of Fudan University
-
Shanghai, Shanghai Municipality, Kina, 200434
- Fullført
- Shanghai Fourth Peoples Hospital Affiliated to Tongji University
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Kina, 301617
- Rekruttering
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciencestuanbo Branch
-
Tianjin, Tianjin Municipality, Kina, 300052
- Fullført
- Tianjin Medical University General Hospital
-
-
Zhejiang
-
Hangzhou, Zhejiang, Kina, 310003
- Rekruttering
- The First Affiliated Hospital, Zhejiang University School of Medicine
-
-
-
-
-
Singapore, Singapore, 119074
- Rekruttering
- National University Hospital Singapore
-
-
-
-
-
Barcelona, Spania, 08036
- Aktiv, ikke rekrutterende
- Hospital Clinic de Barcelona
-
-
-
-
-
Headington, Storbritannia, OX3 7LE
- Rekruttering
- Oxford University Hospitals Nhs Trust Churchill Hospital
-
London, Storbritannia, NW1 2PG
- Rekruttering
- University College Hospital
-
Sutton, Storbritannia, SM2 5PT
- Rekruttering
- Royal Marsden Nhs Foundation Royal Marsden Hospital
-
-
-
-
Seoul Teugbyeolsi
-
GangnamGu, Seoul Teugbyeolsi, Sør -Korea, 06351
- Rekruttering
- Samsung Medical Center
-
SeochoGu, Seoul Teugbyeolsi, Sør -Korea, 06591
- Rekruttering
- The Catholic University of Korea, Seoul St Marys Hospital
-
SeodaemunGu, Seoul Teugbyeolsi, Sør -Korea, 03722
- Rekruttering
- Severance Hospital Yonsei University Health System
-
Seoul, Seoul Teugbyeolsi, Sør -Korea, 03080
- Rekruttering
- Seoul National University Hospital
-
SongpaGu, Seoul Teugbyeolsi, Sør -Korea, 05505
- Rekruttering
- Asan Medical Center
-
-
-
-
-
Aachen, Tyskland, 52074
- Rekruttering
- Universitaetsklinikum Aachen
-
Dresden, Tyskland, 01307
- Rekruttering
- Universitatsklinikum Carl Gustav Carus An Der Technischen Universitat Dresden
-
Hamburg, Tyskland, 20251
- Rekruttering
- Universitatsklinikum Hamburg Eppendorf
-
Würzburg, Tyskland, 97080
- Rekruttering
- Universitatsklinikum Wurzburg
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
-
A confirmed diagnosis of multiple myeloma (must have an M-component in serum and/or urine)
-
Measurable disease defined as:
i. M-spike ≥ 500mg/dL, or ii. Urine protein M-spike of ≥ 200 mg/day, or iii. Serum free light chains ≥ 10 mg/dL, and an abnormal κ:λ ratio
-
Participant has documented relapsed or progressive MM on or after any regimen or who are refractory to the most recent line of therapy.
i. Relapsed MM is defined as previously treated MM that progresses and requires initiation of salvage therapy but does not meet the criteria for refractory MM.
ii. Refractory MM is defined as disease that is nonresponsive (failure to achieve minimal response or development of progressive disease) while on primary or salvage therapy or progresses within 60 days of last therapy.
- In Part 1 and Part 2 Cohorts 1 and 2 participants should have relapsed or progressive disease and have had ≥ 3 prior lines of therapy including a proteasome inhibitor, an IMiD, and an anti-CD38 monoclonal antibody, and no more available approved therapies.
- Participants in Part 2 Cohorts 3, 4, and 5 should have relapsed or progressive disease and have had ≥ 1 prior line of therapy. Prior treatment with carfilzomib is allowed but the patient must not be considered carfilzomib refractory by the investigator.
- Participants in Part 2 Cohorts 6 and 7 should have relapsed or progressive disease and have had 1 to 3 prior lines of therapy and previously treated with a proteasome inhibitor and an IMiD
-
Positivity for t(11;14) translocation must be confirmed by validated fluorescence in situ hybridization (FISH) testing assay in a pre-defined laboratory
a. fresh bone marrow aspirate sample must be collected at screening and sent to central laboratory for t(11;14) FISH testing.
-
Adequate organ function defined as:
- Hemoglobin ≥ 8.0 g/dL within 7 days before first dose of study treatment, (transfusions, in accordance with institutional guidelines, are permitted)
- Platelet count ≥ 75,000/μL, within 7 days before first dose of study treatment, independent of growth factor support and transfusions
- Absolute neutrophil count (ANC) ≥ 1000/mm^3 within 7 days before first dose of study treatment
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x upper limit of normal (ULN) and total bilirubin ≤ 2.0 x ULN N (total bilirubin must be < 3 x ULN for patients with Gilbert's syndrome)
Exclusion Criteria:
-
Participant has any of the following conditions:
- Non secretory MM (Serum free light chains < 10 mg/dL)
- Solitary plasmacytoma
- Active plasma cell leukemia (ie, either 20% of peripheral white blood cells or > 2.0 x 109/L circulating plasma cells by standard differential)
- Waldenström macroglobulinemia (WM)
- Amyloidosis.
- Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes (POEMS) syndrome
- Chronic respiratory disease that requires continuous oxygen
-
Significant cardiovascular disease, including but not limited to:
- Myocardial infarction ≤ 6 months before screening
- Ejection fraction ≤ 50%
- Unstable angina≤ 3 months before screening
- New York Heart Association Class III or IV congestive heart failure
- History of clinically significant arrhythmias (eg, sustained ventricular tachycardia, ventricular fibrillation, or torsades de pointes)
- Heart rate-corrected QT interval > 480 milliseconds based on Fridericia's formula
- History of Mobitz II second-degree or third-degree heart block without a permanent pacemaker in place
- Uncontrolled hypertension at screening, defined as systolic blood pressure > 170 mmHg and diastolic blood pressure > 105 mmHg by ≥ 2 consecutive measurements. Prior therapy with sonrotoclax or other agents inhibiting BCL2 activity (eg, venetoclax)
-
Known infection with human immunodeficiency virus (HIV)
-
Serologic status reflecting active viral hepatitis B (HBV) or viral hepatitis C (HCV) infection as follows:
- Presence of hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb). Participants with presence of HBcAb, but absence of HBsAg, are eligible if HBV DNA is undetectable (limitation of sensitivity < 20 IU/mL) ,), and if they are willing to undergo monthly monitoring for HBV reactivation.
- Presence of HCV antibody. Participants with presence of HCV antibody are eligible if HCV RNA is undetectable (limitation of sensitivity < 15 IU/mL).
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Part 1 Dose Escalation
Dose-escalation and de-escalation to determine maximum tolerated dose (MTD) of sonrotoclax plus dexamethasone, sonrotoclax plus dexamethasone plus carfilzomib, sonrotoclax plus dexamethasone plus daratumumab, and sonrotoclax plus dexamethasone plus pomalidomide. |
Administered orally daily
Andre navn:
Once weekly either orally or intravenously Administered intravenously weekly Administered subcutaneously weekly Administered orally daily |
|
Eksperimentell: Part 2 Cohort Expansion
There will be up to 7 expansion cohorts to further evaluate the safety and efficacy of sonrotoclax monotherapy, sonrotoclax plus dexamethasone in combination with dexamethasone plus carfilzomib, and in combination with dexamethasone plus daratumumab |
Administered orally daily
Andre navn:
Once weekly either orally or intravenously Administered intravenously weekly |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Del 1 og 2: Antall deltakere som rapporterer en eller flere behandlingsoppførende bivirkninger (TEEES), alvorlige bivirkninger (SAE), bivirkninger som fører til seponering og bivirkninger av spesiell interesse (AESIS).
Tidsramme: Opptil 30 dager etter siste dose studiemedisin
|
Opptil 30 dager etter siste dose studiemedisin
|
|
|
Part 1: Number Of Participants Experiencing Dose-limiting Toxicities (DLTs)
Tidsramme: Up to 28 days
|
DLTs will be based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 and will include most grade 3 or higher events, as defined in the protocol. |
Up to 28 days
|
|
Part 2: Overall response rate (ORR) as Assessed by Investigator
Tidsramme: Approximately 4 years
|
Defined as the percentage of participants who achieved a stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) per International Myeloma Working Group (IMWG) criteria |
Approximately 4 years
|
|
Part 2: Very Good Partial Response (VGPR) or Better Response Rate as Assessed by Investigator
Tidsramme: Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years]
|
Defined as the percentage of participants with a documented VGPR or better (including sCR, CR, and VGPR) |
Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years]
|
|
Part 2: Complete Response (CR) or Stringent Complete Response (sCR) as Assessed by Investigator
Tidsramme: Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years])
|
defined as the percentage of participants with a documented CR or sCR |
Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years])
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Del 1: Område under plasmakonsentrasjonstidskurvetid 0 til den siste målbare konsentrasjonen (Auclast) etter en enkelt dose sonrotoclax
Tidsramme: Syklus 1 (hver syklus er opptil 28 dager)
|
Syklus 1 (hver syklus er opptil 28 dager)
|
|
|
Del 1: Maksimal observert plasmakonsentrasjon (Cmax) etter en enkelt dose sonrotoclax
Tidsramme: Syklus 1 (hver syklus er opptil 28 dager)
|
Syklus 1 (hver syklus er opptil 28 dager)
|
|
|
Del 1: Tid for å nå Cmax (Tmax) etter en enkelt dose sonrotoclax
Tidsramme: Syklus 1 (hver syklus er opptil 28 dager)
|
Syklus 1 (hver syklus er opptil 28 dager)
|
|
|
Del 1: I Steady-State: AUC Last, SS
Tidsramme: Syklus 2 (hver syklus er opptil 28 dager)
|
Syklus 2 (hver syklus er opptil 28 dager)
|
|
|
Del 1: I Steady-State: Cmax, SS
Tidsramme: Syklus 2 (hver syklus er opptil 28 dager)
|
Syklus 2 (hver syklus er opptil 28 dager)
|
|
|
Del 1: I Steady-State: Trough Plasma Concentration (CTrough) SS
Tidsramme: Syklus 2 (hver syklus er opptil 28 dager)
|
Syklus 2 (hver syklus er opptil 28 dager)
|
|
|
Del 1: I Steady-State: Time to Reach Cmax (Tmax, SS)
Tidsramme: Syklus 2 (hver syklus er opptil 28 dager)
|
Syklus 2 (hver syklus er opptil 28 dager)
|
|
|
Part 2: Time to response (TTR) as Assessed by Investigator
Tidsramme: Approximately 4 years
|
TTR is defined as the time from start of treatment (for nonrandomized cohorts) or date of randomization (for randomized cohorts to first documentation of response of Partial Response (PR) or better |
Approximately 4 years
|
|
Part 2: Duration of response (DOR) as Assessed by Investigator
Tidsramme: Approximately 4 years
|
DOR is defined as the time from the date of the first documented response (PR or better) after treatment initiation until the date of first documented disease progression or death due to any cause, whichever occurs first. DOR will be analyzed only for patients who have achieved an overall response of at least PR. The distribution of DOR will be summarized by the Kaplan-Meier method. |
Approximately 4 years
|
|
Part 2: Progression-free survival (PFS) as Assessed by Investigator
Tidsramme: Approximately 4 years
|
PFS is defined as time from start of treatment (for nonrandomized cohorts) or date of randomization (for randomized cohorts) to the first documentation of disease progression or death, whichever occurs first |
Approximately 4 years
|
|
Part 2: Overall survival (OS) as Assessed by Investigator
Tidsramme: Approximately 4 years
|
OS defined as the time from start of treatment (for nonrandomized cohorts) or date of randomization (for randomized cohorts to the date of death due to any cause |
Approximately 4 years
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Vaskulære sykdommer
- Kardiovaskulære sykdommer
- Neoplasmer
- Sykdommer i immunsystemet
- Neoplasmer etter histologisk type
- Hematologiske sykdommer
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Neoplasmer, plasmacelle
- Hemostatiske lidelser
- Paraproteinemier
- Blodproteinforstyrrelser
- Hemoragiske lidelser
- Hemic og lymfatiske sykdommer
- Multippelt myelom
- Polysykliske forbindelser
- Gravadienes
- Gravaner
- Steroider
- Smeltede ringforbindelser
- Steroider, fluorert
- Gravadienetrioler
- Deksametason
- carfilzomib
- pomalidomid
- daratumumab
Andre studie-ID-numre
- BGB-11417-105
- 2021-003614-39 (EudraCT-nummer)
- U1111-1277-5444 (Annen identifikator: UTN Number)
- 2023-507751-30-00 (Ctis)
- CTR20231932 (Annen identifikator: ChinaDrugTrials)
- 2023 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.
BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.
Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
IPD-delingstidsramme
See plan description
Tilgangskriterier for IPD-deling
See plan description
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- CSR
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .